J
Julio Rosenstock
Researcher at University of Texas Southwestern Medical Center
Publications - 423
Citations - 39792
Julio Rosenstock is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 94, co-authored 364 publications receiving 32784 citations. Previous affiliations of Julio Rosenstock include Medical City Dallas Hospital & Pfizer.
Papers
More filters
Journal Article
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): A randomized, double-blind, placebo-control
Julio Rosenstock,Vlado Perkovic,John H. Alexander,Mark E. Cooper,Nikolaus Marx,Michael J. Pencina,Robert D. Toto,Christoph Wanner,Bernard Zinman,David Baanstra,Egon Pfarr,Michaela Mattheus,Uli C. Broedl,HJ Woerle,Jyothis T. George,E von,Darren K. McGuire +16 more
Journal ArticleDOI
Breast cancer and diabetes.
Philippe Autier,Alice Koechlin,Chris Robertson,Maria Bota,Mathieu Boniol,Derek LeRoith,Geremia B. Bolli,Julio Rosenstock,Peter Boyle +8 more
TL;DR: Serum insulin and c-peptide were associated with breast cancer at post- menopausal ages but not at pre-menopausal ages, while fasting glucose and glycaemic index were not associated.
Journal ArticleDOI
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
Muhammad Usman,Tariq Jamal Siddiqi,Stefan D. Anker,George L. Bakris,Deepak Bhatt,Gerasimos Filippatos,Gregg C. Fonarow,Stephen J. Greene,James L. Januzzi,Muhammad Shahzeb Khan,Mikhail Kosiborod,Darren K. McGuire,Ileana L. Piña,Julio Rosenstock,Muthiah Vaduganathan,Subodh Verma,Shelley Zieroth,Javed Butler +17 more
TL;DR: In this article , the authors conducted a meta-analysis assessing the effects of SGLT2 inhibitors on heart failure outcomes and cardiovascular (CV) death in patients with varying combinations of type 2 diabetes mellitus (T2DM), HF, and chronic kidney disease (CKD) across different patient populations.
Journal ArticleDOI
Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles.
Richard M. Bergenstal,Mary L. Johnson,Vanita R. Aroda,Ronald L. Brazg,Darlene M. Dreon,Juan P. Frias,Davida F. Kruger,Mark E. Molitch,Deborah M. Mullen,Mark Peyrot,Sara Richter,Julio Rosenstock,Pierre Serusclat,Carl Vance,Ruth S. Weinstock,Brian L. Levy +15 more
TL;DR: CeQur Simplicity as mentioned in this paper is a 3-day insulin delivery patch designed to meet mealtime insulin requirements, which is a recently reported 48-week, randomized, multicenter, interven...
Journal ArticleDOI
Efficacy and Safety of Liraglutide vs. Placebo When Added to Basal Insulin Analogues in Subjects with Type 2 Diabetes (LIRA-ADD2BASAL): A Randomized, Placebo-Controlled Trial
J Robin Conway,Andrew J. Ahmann,Helena W. Rodbard,Julio Rosenstock,Jorma Lahtela,Luis De Loredo,Karen Tornøe,Anand Boopalan,Michael A. Nauck +8 more